Profit

NSE Symbol: | BSE Code: | ISIN: | Sector:

  • Add to Portfolio
  • Add to Watchlist
  • Add to Alert
  • Add to Message
Add to Portfolio
NSE
33.90
Change Change %
0.75 2.26%

Updated:23 Aug, 2019, 15:59 PM IST

BSE
34.15
Change Change %
0.95 2.86%

Updated:23 Aug, 2019, 16:01 PM IST

Ind–Swift Laboratories is a part of the Ind–swift Group and is based at Chandigarh, India. It has been promoted by Ind–Swift Limited in a joint venture with the Punjab State Industrial Development Corporation Limited (PSIDC). The group has established a strong reputation as innovators in the Indian pharmaceutical industry. 

Ind–Swift Laboratories Ltd. went public in 1997 and concentrated on the manufacturing of Active Pharmaceutical Ingredients (API). Its strength in organic synthetic chemistry resulted in the company emerging as the pioneer for a number of products both in the national and international markets. As the company built up vast skills in the area of research and development, quality systems as well as matters relating to regulatory compliance, it began establishing a presence in the highly regulated markets of the world.

Over a short period of time, Ind–Swift Laboratories Ltd. has emerged as a respectable and dependable supplier of Bulk–Actives in more than 40 countries. Not only are the company's plants built as per USFDA, the company employs current Good Manufacturing Practices (cGMP) also, which are recognised and accepted in the stringent regulated markets. This includes a responsible commitment to the environment.   To leverage its quality commitment, the Company has drawn out a long term strategy of emerging as a powerful force in the regulated markets as drugs worth over US$ 80 billion goes off patent during this decade.

The company's shares are listed on the Bombay, National, Ludhiana and Delhi stock exchanges.

Product range of the company include:

  • Macrolide antibiotics
  • Cardiovascular
  • Anti histamine
  • Anti diabetic
  • Analgesic
  • Aromatase inhibtors
  • Anti depressant
  • Alcohol absistence

MANUFACTURING

Ind–Swift's manufacturing facilities are second to none, and in fact has grown over the years to accommodate a wide range of products. However, even with the spiraling increase in production, it has never compromised on Quality, which has always remained its mantra.

The company has put to operation three new manufacturing facilities covered under its Rs 1 billion expansion plans. The three facilities were a dedicated facility to manufacture Statins ( installed capacity of 40TPA) , a new dedicated facility for an Anti–Histamine drug ( installed capacity 27 TPA) and a New API facility at Samba, Jammu (installed capacity of 50TPA ) . All these facilities conform to USFDA standards and have been put to commercial production. The new facility at Jammu is situated in a tax free zone and shall be entitled to tax holiday for a period of ten years.

Strict Quality Control

Equipped with state–of–the–art quality testing equipment and well trained personnel, Ind–Swift maintains strict quality control, storage to delivery in accordance with GMP and ISO 9002. Quality of products meet the respective requirement of USP/BP/EP/JP etc., as per the international quality standards.

Manufacturing Facilities

  • 1,50,000 sq. ft. covered area
  • 5 Dedicated Blocks operating as per US FDA guidelines.
  • 132 Stainless Steel and Glass Lined Reaction Vessels with capacities ranging from 50 to 6000 liters. (Total Volume 245 kilo liters)
  • 3 Automated Fluidized Bed Coaters with capacity of manufacturing 3 MT of Granules per month.
  • cGMP Pilot Plant having 7 reaction vessels with capacities ranging from 250 to 1000 liters. (Total Volume 3.63 kilo liters)
  • Fully Automated Solvent Recovery System
  • Biological Waste Water Treatment Plant

Future plans

While development of new molecules will remain its core activity in the post patent era the Company will also focus on alternate and non–infringing routes for the drugs whose patent will expire in coming years.

To enter the regulated markets like USA, EU, Australia, and New Zealand, the company is focusing on getting its manufacturing plant approved by regulatory agencies like USFDA, TGA and MCA.

A new R&D Center with investment of $ 5 Million is already planned in Mohali with a focus to develop NCEs.

Top